BRPI0918045A2 - compostos de carboxamida heterocíclicos - Google Patents
compostos de carboxamida heterocíclicosInfo
- Publication number
- BRPI0918045A2 BRPI0918045A2 BRPI0918045A BRPI0918045A BRPI0918045A2 BR PI0918045 A2 BRPI0918045 A2 BR PI0918045A2 BR PI0918045 A BRPI0918045 A BR PI0918045A BR PI0918045 A BRPI0918045 A BR PI0918045A BR PI0918045 A2 BRPI0918045 A2 BR PI0918045A2
- Authority
- BR
- Brazil
- Prior art keywords
- carboxamide compounds
- heterocyclic carboxamide
- heterocyclic
- compounds
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9797908P | 2008-09-18 | 2008-09-18 | |
| PCT/JP2009/066840 WO2010032875A2 (en) | 2008-09-18 | 2009-09-17 | Heterocyclic carboxamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0918045A2 true BRPI0918045A2 (pt) | 2015-12-01 |
Family
ID=41682377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0918045A BRPI0918045A2 (pt) | 2008-09-18 | 2009-09-17 | compostos de carboxamida heterocíclicos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110166161A1 (pt) |
| EP (1) | EP2331507A2 (pt) |
| JP (1) | JP2012502882A (pt) |
| KR (1) | KR20110060894A (pt) |
| CN (1) | CN102159547A (pt) |
| BR (1) | BRPI0918045A2 (pt) |
| CA (1) | CA2737738A1 (pt) |
| MX (1) | MX2011002825A (pt) |
| WO (1) | WO2010032875A2 (pt) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US8748623B2 (en) | 2009-02-17 | 2014-06-10 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
| GB201018996D0 (en) * | 2010-11-10 | 2010-12-22 | Amakem Nv | Novel ROCK inhibitors |
| AU2011293612B2 (en) * | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| TWI548621B (zh) | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
| BR112014012396B1 (pt) * | 2011-11-23 | 2020-08-25 | Portola Pharmaceuticals, Inc | inibidores de pirazina quinase, composição, método in vitro para inibição de quinase syk ou via de transdução de sinal, uso dos referidos inibidores e kit |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| EA033530B1 (ru) | 2014-12-16 | 2019-10-31 | Signal Pharm Llc | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида |
| JP6903577B2 (ja) | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ，エルエルシー | 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法 |
| WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| US10252981B2 (en) | 2015-07-24 | 2019-04-09 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| AR110401A1 (es) | 2016-12-21 | 2019-03-27 | Chiesi Farm Spa | Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa |
| WO2018138293A1 (en) | 2017-01-30 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
| EP3652164B1 (en) * | 2017-07-12 | 2023-06-21 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
| CN110869361B (zh) * | 2017-07-12 | 2023-06-02 | 百时美施贵宝公司 | 用于治疗心力衰竭的rock的五元氨基杂环和5,6元或6,6元双环氨基杂环抑制剂 |
| TW201908293A (zh) * | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| US11147812B2 (en) | 2017-09-07 | 2021-10-19 | Chiesi Farmaceutici S.P.A. | Tyrosine analogues derivatives as Rho-kinase inhibitors |
| WO2019121223A1 (en) | 2017-12-18 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Meta tyrosine derivatives as rho-kinase inhibitors |
| EP3728248B1 (en) | 2017-12-18 | 2022-02-02 | Chiesi Farmaceutici S.p.A. | Azaindole derivatives as rho-kinase inhibitors |
| MA51284A (fr) | 2017-12-18 | 2021-05-26 | Chiesi Farm Spa | Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho |
| CN108101885A (zh) * | 2017-12-31 | 2018-06-01 | 佛山市赛维斯医药科技有限公司 | 含异丙胺和硝基噻吩酰胺类结构化合物、其制备方法及用途 |
| CN107935987A (zh) * | 2017-12-31 | 2018-04-20 | 佛山市赛维斯医药科技有限公司 | 含甲基萘和噻吩酰胺结构的rock抑制剂、制备方法及其用途 |
| CN108047197A (zh) * | 2017-12-31 | 2018-05-18 | 佛山市赛维斯医药科技有限公司 | 硝基噻吩酰胺rock抑制剂、制备方法及其用途 |
| CN108047194A (zh) * | 2017-12-31 | 2018-05-18 | 佛山市赛维斯医药科技有限公司 | 含甲基萘和丙二醇噻吩酰胺类化合物、制备方法及其用途 |
| CN108191820A (zh) * | 2017-12-31 | 2018-06-22 | 佛山市赛维斯医药科技有限公司 | 一种含异丙胺和噻吩酰胺类结构的化合物 |
| CN108558823A (zh) * | 2017-12-31 | 2018-09-21 | 佛山市赛维斯医药科技有限公司 | 一类腈基噻吩酰胺rock抑制剂、制备方法及其用途 |
| CN108047193A (zh) * | 2017-12-31 | 2018-05-18 | 佛山市赛维斯医药科技有限公司 | 烷氧噻吩酰胺类rock抑制剂、制备方法及其用途 |
| CN108218829A (zh) * | 2017-12-31 | 2018-06-29 | 佛山市赛维斯医药科技有限公司 | 一种噻吩酰胺类rock抑制剂、制备方法及其用途 |
| CN108129453A (zh) * | 2017-12-31 | 2018-06-08 | 佛山市赛维斯医药科技有限公司 | 一种含甲基萘和丙二醇噻吩酰胺类结构的rock抑制剂 |
| CN107973776A (zh) * | 2017-12-31 | 2018-05-01 | 佛山市赛维斯医药科技有限公司 | 一种噻吩酰胺类结构化合物及其用途 |
| CN107935986A (zh) * | 2017-12-31 | 2018-04-20 | 佛山市赛维斯医药科技有限公司 | 异丙胺和卤代噻吩酰胺类结构化合物、其制备方法及用途 |
| CN108129452A (zh) * | 2017-12-31 | 2018-06-08 | 佛山市赛维斯医药科技有限公司 | 一种含异丙基萘和丙二醇硝基噻吩酰胺类化合物及其用途 |
| CN107973777A (zh) * | 2017-12-31 | 2018-05-01 | 佛山市赛维斯医药科技有限公司 | 一种含甲基萘和丙二醇噻吩酰胺类rock抑制剂及其用途 |
| CN108047195A (zh) * | 2017-12-31 | 2018-05-18 | 佛山市赛维斯医药科技有限公司 | 一种含丙二醇腈基噻吩酰胺类化合物及其用途 |
| CN107915717A (zh) * | 2017-12-31 | 2018-04-17 | 佛山市赛维斯医药科技有限公司 | 一类含异丙基萘和丙二醇噻吩酰胺类化合物及其用途 |
| AR114926A1 (es) | 2018-06-13 | 2020-10-28 | Chiesi Farm Spa | Derivados de azaindol como inhibidores de rho-quinasa |
| TW202019923A (zh) | 2018-07-16 | 2020-06-01 | 義大利商吉斯藥品公司 | 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物 |
| CA3202126A1 (en) | 2020-12-15 | 2022-06-23 | Fabio Rancati | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
| EP4263548A1 (en) | 2020-12-15 | 2023-10-25 | Chiesi Farmaceutici S.p.A. | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
| AU2021402528A1 (en) | 2020-12-15 | 2023-07-27 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
| WO2023110700A1 (en) | 2021-12-13 | 2023-06-22 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho-kinase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ334613A (en) * | 1996-08-12 | 2002-02-01 | Welfide Corp | Pharmaceutical agents comprising Rho kinase inhibitor |
| ES2372572T3 (es) * | 1998-08-17 | 2012-01-23 | Senju Pharmaceutical Co., Ltd. | Agente para profilaxis y tratamiento de glaucoma. |
| TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| US20040180925A1 (en) * | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
| AU2003220935A1 (en) * | 2002-04-03 | 2003-10-13 | Sumitomo Pharmaceuticals Company, Limited. | Benzamide derivatives |
| US7094789B2 (en) * | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
| CN100383140C (zh) * | 2002-09-12 | 2008-04-23 | 麒麟麦酒株式会社 | 具有激酶抑制活性的异喹啉衍生物和包含异喹啉衍生物的药剂 |
| TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US7160894B2 (en) * | 2003-06-06 | 2007-01-09 | Asahi Kasei Pharma Corporation | Tricyclic compound |
| CN1863779B (zh) * | 2003-10-15 | 2010-05-05 | 宇部兴产株式会社 | 吲唑衍生物 |
| EP1697307B1 (en) * | 2003-12-12 | 2014-03-12 | Eli Lilly & Company | Opioid receptor antagonists |
| EP2786995A1 (en) * | 2004-03-30 | 2014-10-08 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| WO2006135383A2 (en) * | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
| CN101506165B (zh) * | 2006-08-15 | 2012-07-04 | 霍夫曼-拉罗奇有限公司 | 苯基、吡啶和喹啉衍生物 |
-
2009
- 2009-09-17 EP EP09748156A patent/EP2331507A2/en not_active Withdrawn
- 2009-09-17 WO PCT/JP2009/066840 patent/WO2010032875A2/en active Application Filing
- 2009-09-17 KR KR1020117005434A patent/KR20110060894A/ko not_active Application Discontinuation
- 2009-09-17 JP JP2011510770A patent/JP2012502882A/ja not_active Withdrawn
- 2009-09-17 CN CN2009801368126A patent/CN102159547A/zh active Pending
- 2009-09-17 MX MX2011002825A patent/MX2011002825A/es not_active Application Discontinuation
- 2009-09-17 US US13/061,855 patent/US20110166161A1/en not_active Abandoned
- 2009-09-17 CA CA2737738A patent/CA2737738A1/en not_active Abandoned
- 2009-09-17 BR BRPI0918045A patent/BRPI0918045A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2737738A1 (en) | 2010-03-25 |
| KR20110060894A (ko) | 2011-06-08 |
| MX2011002825A (es) | 2011-04-05 |
| WO2010032875A2 (en) | 2010-03-25 |
| CN102159547A (zh) | 2011-08-17 |
| JP2012502882A (ja) | 2012-02-02 |
| WO2010032875A3 (en) | 2010-06-10 |
| US20110166161A1 (en) | 2011-07-07 |
| EP2331507A2 (en) | 2011-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020004I2 (el) | Eνωση διαμινο ετεροκυκλικου καρβοξαμιδιου | |
| BRPI0918045A2 (pt) | compostos de carboxamida heterocíclicos | |
| BRPI0906705A2 (pt) | Composto heterocíclicos | |
| BRPI0916233A2 (pt) | compostos heterocíclicos antivirais | |
| DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
| BRPI0920707A2 (pt) | compostos | |
| DK2242759T3 (da) | Forbindelser | |
| DK2308877T3 (da) | Imidazopyridin-2-on-derivater | |
| DK2340021T3 (da) | Substituerede pyrrolidin-2-carboxamider | |
| SMT201600045B (it) | Composti tetraciclinici c7-fluoro sostituiti | |
| BRPI0918760A2 (pt) | compostos morfinanos | |
| BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
| BR112012008061A2 (pt) | compostos de oxima heterocíclica | |
| BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
| BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
| BRPI0923497A2 (pt) | derivados de piridazinona | |
| DK2297162T3 (da) | Forbindelser | |
| BRPI0924121A2 (pt) | compostos antivirais heterocíclicos | |
| DK2275414T3 (da) | Cyclopentylacrylamidderivat | |
| ATE545635T1 (de) | Substituierte n-oxidpyrazinderivate | |
| BRPI0906357A2 (pt) | Derivados de oxazepinopirimidona arilamida substituídos | |
| BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
| DK2617420T3 (da) | Heterocykliske phenoxymethylforbindelser | |
| BR112012010238A2 (pt) | compostos heterocíclicos pesticidas | |
| ATE534634T1 (de) | 2-phenyl-4-cyclopropyl-pyrimidinderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |